Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01636076
Registration number
NCT01636076
Ethics application status
Date submitted
5/07/2012
Date registered
10/07/2012
Date last updated
17/11/2014
Titles & IDs
Public title
Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Query!
Scientific title
A Randomized, Double-blind, 12-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of QMF149 (150 µg/160 µg o.d.) Compared With Salmeterol Xinafoate/Fluticasone Propionate (50 µg/500 µg b.i.d.) in Patients With Chronic Obstructive Pulmonary Disease
Query!
Secondary ID [1]
0
0
2012-001172-12
Query!
Secondary ID [2]
0
0
CQMF149F2202
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
COPD
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - QMF149
Treatment: Drugs - Salmeterol
Experimental: QMF149 - QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device
Active Comparator: Salmeterol xinafoate/fluticasone propionate - Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®
Treatment: Drugs: QMF149
delivered via Concept1 device
Treatment: Drugs: Salmeterol
delivered via Accuhaler®
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for Trough FEV1 (L) on Day 85
Query!
Assessment method [1]
0
0
Spirometry is conducted according to the global standard. Trough FEV1 is defined as the average of the 23 hour 10 minute and 23 hour 45 minute post dose FEV1 readings.
Query!
Timepoint [1]
0
0
12 weeks
Query!
Secondary outcome [1]
0
0
Trough FEV1 After First Dose and After 4 Weeks of Treatment
Query!
Assessment method [1]
0
0
Spirometry is conducted according to the global standard. FEV1 is measured at pre-dose and post dose up to 1 hours on Day 1 and Day 28; 24 hours post-dose on Day 29 and 85. In a subset of approximately 60 patients, FEV1 is measured up to 20 hours postdose on Day 28 and Day 84.
Query!
Timepoint [1]
0
0
Day 1 and Day 85
Query!
Secondary outcome [2]
0
0
Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for FEV1 (L), by Visit and Timepoint
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Day 1 through day 85
Query!
Secondary outcome [3]
0
0
Forced Vital Capacity (FVC) at Each Timepoint
Query!
Assessment method [3]
0
0
Spirometry is conducted according to the global standard. FVC is measured at pre-dose and post dose up to 4 hour on Day 1, Day 28, and Day 84, at post dose 12 hour, 23 hour 10 minute and 23 hour 45 minutes on Day 2 and Day 29, and at pre-dose 50 min and 15 min on Day 2, Day 28, and Day 84.
Query!
Timepoint [3]
0
0
Day 1, Day 2, Day 28, Day , Day 29, Day 84, Day 85
Query!
Secondary outcome [4]
0
0
FEV1/FVC at Each Timepoint
Query!
Assessment method [4]
0
0
Spirometry is conducted according to the global standard. FEV1/FVC is measured at pre-dose and post dose up to 4 hour on Day 1, Day 28, and Day 84, at post dose 12 hour, 23 hour 10 minute and 23 hour 45 minutes on Day 2 and Day 29, and at pre-dose 50 min and 15 min on Day 2, Day 28, and Day 84.
Query!
Timepoint [4]
0
0
Day 1, Day 2, Day 28, Day , Day 29, Day 84, Day 85
Query!
Secondary outcome [5]
0
0
FEV1 (L) on Day 1 Between-treatment Comparisons of AUC (5min - 4h)
Query!
Assessment method [5]
0
0
Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), Scheduled (not actual) time points are to be used. The standardized AUC(5 min - 4 h) for FEV1 will be summarized by treatment.
Query!
Timepoint [5]
0
0
Day 1
Query!
Secondary outcome [6]
0
0
FEV1 AUC (5 Min-4 h),
Query!
Assessment method [6]
0
0
Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), (5 min-24 h) is measured after the first dose on Day 1 and on Day 28 and Day 84 in a subset of approximately 60 patients. Scheduled (not actual) time points are to be used. The interpretation of FEV1 at time 0 is the baseline value at the randomization visit and the latest pre-dose value (-50 min or -15 min) at subsequent visits. The standardized AUC(5 min - 4 h) for FEV1 will be summarized by treatment. The same will be repeated for standardized AUC for FEV1 between 5 min and 24 hours post morning dose.
Query!
Timepoint [6]
0
0
Day 1(Baseline), Day 28, Day 84
Query!
Secondary outcome [7]
0
0
Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for AUC (5 Min - 23 h 45 Min) for FEV1 (L) on Day 28 and Day 84 (Full Analysis Set, 24-h Profiling Subgroup)
Query!
Assessment method [7]
0
0
Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), (5 min-24 h) is measured after the first dose on Day 1 and on Day 28 and Day 84 in a subset of approximately 60 patients. Scheduled (not actual) time points are to be used. The interpretation of FEV1 at time 0 is the baseline value at the randomization visit and the latest pre-dose value (-50 min or -15 min) at subsequent visits. The standardized AUC(5 min - 4 h) for FEV1 will be summarized by treatment. The same will be repeated for standardized AUC for FEV1 between 5 min and 24 hours post morning dose.
Query!
Timepoint [7]
0
0
Day 28, Day 84
Query!
Secondary outcome [8]
0
0
The Usage of Rescue Medication (Short Acting ß2-agonist)
Query!
Assessment method [8]
0
0
Participants record the number of puffs of rescue medication taken in the previous 12 hours each morning and evening throughout the 12 week treatment period.
Query!
Timepoint [8]
0
0
12 weeks
Query!
Secondary outcome [9]
0
0
The Overall Change in Usage of Rescue Medication (Short Acting ß2-agonist) .
Query!
Assessment method [9]
0
0
This value represents the percent of days in the study where no rescue medication was needed.
Query!
Timepoint [9]
0
0
Baseline to 12 weeks
Query!
Secondary outcome [10]
0
0
Patient Reported Outcome Measures: SGRQ (St. George's Respiratory Questionnaire)
Query!
Assessment method [10]
0
0
A Total and three component scores are calculated: Symptoms; Activity; Impacts. Each component of the questionnaire is scored separately:The score for each component is calculated separately by dividing the summed weights by the maximum possible weight for that component and expressing the result as a percentage: Score = 100 x Summed weights from all positive items in that component divided by Sum of weights for all items in that component The Total score is calculated in similar way: Score = 100 x Summed weights from all positive items in the questionnaire divided by Sum of weights for all items in the questionnaire Sum of maximum possible weights for each component and Total: Symptoms 566.2 Activity 982.9 Impacts 1652.8 Total (sum of maximum for all three components) 3201.9 The proportion of patients who achieve a clinically important improvement of at least 4 units in the total SGRQ will be analyzed. The higher the score the more symptoms of disease are present.
Query!
Timepoint [10]
0
0
4 and 12 weeks
Query!
Secondary outcome [11]
0
0
Analysis of the Proportion of Subjects With a Clinically Important Improvement of >=1 Point in the TDI (Transitional Dyspnoea Index)Focal Score by Visit
Query!
Assessment method [11]
0
0
A TDI focal score of =1 is considered to be a clinically important improvement from baseline. Analysis of the proportion of subjects with a clinically important improvement of >=1 point in the TDI focal score, by visit
Query!
Timepoint [11]
0
0
4 and 12 weeks
Query!
Secondary outcome [12]
0
0
Patient Reported Outcome Measures: COPD Assessment Test
Query!
Assessment method [12]
0
0
It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.
Query!
Timepoint [12]
0
0
Baseline, 4 and 12 weeks
Query!
Secondary outcome [13]
0
0
Patient Reported Outcome Measures: Medical Outcome Study (MOS) Sleep Scale: Without Quantity Subscale
Query!
Assessment method [13]
0
0
Scoring the MOS Sleep Survey is a two-step process:• All items are scored so that a high score reflects more of the attribute implied by the scale name. Each item is converted to a 0 to 100 possible range so that the lowest and highest possible scores are set at 0 and 100, respectively. In this format, scores represent the achieved percentage of the total possible score. For example, a score of 50 represents 50% of the highest possible score.
• Second, items within each scale are averaged together to create the 7 scale scores. Scales with at least one item answered can be used to generate a scale score. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Scores represent the average for all items in the scale that the respondent answered. An additional measure is based on the average number of hours sleep each night during the past 4 weeks and are described in outcome measure 15.
Query!
Timepoint [13]
0
0
Baseline, 4 and 12 weeks
Query!
Secondary outcome [14]
0
0
Patient Reported Outcome Measures: Medical Outcome Study (MOS) Sleep Scale: Sleep Quantity Subscale
Query!
Assessment method [14]
0
0
The sleep quantity subscale,which refers to question 2 of the PRO: On average, how many hours did you sleep each night during the past 4 weeks. More hours of sleep indicate better outcome.
Query!
Timepoint [14]
0
0
Baseline, 4 and 12 weeks
Query!
Secondary outcome [15]
0
0
Summary Statistics of COPD Exacerbations over12 Weeks as Defined by Chronic Pulmonary Disease Tool (EXACT)
Query!
Assessment method [15]
0
0
The EXACT is a 14-item electronic questionnaire designed to detect the frequency, severity, and duration of exacerbations in patients with COPD.
Query!
Timepoint [15]
0
0
12 weeks
Query!
Secondary outcome [16]
0
0
Time to First COPD Exacerbation
Query!
Assessment method [16]
0
0
Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates. The reported measure will detail the percentage of participants that were event free of a specified event.
Query!
Timepoint [16]
0
0
12 weeks
Query!
Secondary outcome [17]
0
0
Annual Rate of COPD Exacerbations
Query!
Assessment method [17]
0
0
Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.
Query!
Timepoint [17]
0
0
12 weeks
Query!
Secondary outcome [18]
0
0
Duration (in Days) of COPD Exacerbations
Query!
Assessment method [18]
0
0
Duration and number of the COPD exacerbation will be analyzed by the negative binomial regression model including treatment, country, smoking status, and COPD severity as factors and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.
Query!
Timepoint [18]
0
0
12 weeks
Query!
Secondary outcome [19]
0
0
Percentage of Patients With at Least One Exacerbation up to Week 12
Query!
Assessment method [19]
0
0
Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates. The reported measure will detail the percentage of participants that had an exacerbation up to week 12. Less exacerbations reflect a better outcome.
Query!
Timepoint [19]
0
0
12 weeks
Query!
Secondary outcome [20]
0
0
Time (in Days) to Permanent Study Discontinuation Due to COPD Exacerbation
Query!
Assessment method [20]
0
0
Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.
Query!
Timepoint [20]
0
0
12 weeks
Query!
Secondary outcome [21]
0
0
The Percentage of Patients Who Permanently Discontinued Due to COPD Exacerbation
Query!
Assessment method [21]
0
0
Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.
Query!
Timepoint [21]
0
0
12 weeks
Query!
Secondary outcome [22]
0
0
Total Amount (in Doses) of Systemic Corticosteroid Used to Treat COPD Exacerbation During the 12 Week Treatment Period
Query!
Assessment method [22]
0
0
Total amount (in doses) of systemic corticosteroid used to treat COPD exacerbation will be summarized descriptively by treatment group per each systemic corticosteroid.
Query!
Timepoint [22]
0
0
12 weeks
Query!
Secondary outcome [23]
0
0
Plasma Cortisol Concentrations at Each Timepoint
Query!
Assessment method [23]
0
0
Plasma cortisol to be measured in a subset of approximately 60 patients via central laboratory. Blood sample for Plasma cortisol is collected at pre-dose and post dose up to 4 hour on Day 1, up to 12 hours post-dose on Day 28 and Day 84, and 23 hour 35 minute on Day 2, Day 29, and Day 85, and at pre-dose 25 minute on Day 28, and Day 84.
Query!
Timepoint [23]
0
0
Day 1, Day 28, Day 84
Query!
Secondary outcome [24]
0
0
Plasma Drug Concentrations (Pharmacokinetics) at Each Timepoint
Query!
Assessment method [24]
0
0
Plasma indacaterol and mometasone furoate is to be measured in a subset of approximately 60 patients via central laboratory. Blood samples are collected at pre-dose on Day 1, 29, and 84; and post dose up to 4 hour on Day 1, up to 12 hours on Day 28 and 84. For sparse pharmacokinetic testing, blood samples will be collected at 23h 35 min post-dose following morning dose administration on Day 28 and 84, in all patients participating in this study.
Query!
Timepoint [24]
0
0
Day 1, 29, 84
Query!
Secondary outcome [25]
0
0
Pharmacokinetic Parameter: Cmax
Query!
Assessment method [25]
0
0
Maximum observed plasma concentration after drug administration is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.
Query!
Timepoint [25]
0
0
Day 28, 84
Query!
Secondary outcome [26]
0
0
Pharmacokinetic Parameter--Tmax
Query!
Assessment method [26]
0
0
Time to reach the maximum plasma concentration after drug administration is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.
Query!
Timepoint [26]
0
0
Day 28, 84
Query!
Secondary outcome [27]
0
0
Pharmacokinetic Parameter--AUC0-t
Query!
Assessment method [27]
0
0
Area under the plasma concentration time curve from time zero to time "t" post-dose is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.
Query!
Timepoint [27]
0
0
Day 28, 84
Query!
Eligibility
Key inclusion criteria
- Patients with moderate to very severe COPD (GOLD 2 to GOLD 4) according to the 2011
Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines
- Patients with a post-bronchodilator FEV1 < 70% of the predicted normal, and a
post-bronchodilator FEV1/FVC < 0.70 at run-in (Visit 101).
- Current or ex-smokers who have a smoking history of at least 10 pack years (defined as
the number of packs of 20 cigarettes smoked per day multiplied by number of years the
patient smoked. e.g.10 pack years = 1 pack /day x 10 yrs, or ½ pack/day x 20 yrs). An
ex-smoker may be defined as a subject who has not smoked for = 6 months at screening.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients who have had a COPD exacerbation that required treatment with antibiotics
and/or oral corticosteroids and/or hospitalization in the 6 weeks prior to screening
(Visit 1).
- Patients who develop a COPD exacerbation between screening (Visit 1) and treatment
(Visit 201) will not be eligible but will be permitted to be re-screened after a
minimum of 6 weeks after the resolution of the COPD exacerbation.
- Patients who have had a respiratory tract infection within 4 weeks prior to screening
Visit 1.
- Patients who develop a respiratory tract infection between screening (Visit 1) and
treatment (Visit 201) will not be eligible, but will be permitted to be re-screened 4
weeks after the resolution of the respiratory tract infection.
- Patients requiring long term oxygen therapy prescribed for >12 hours per day.
- Patients with, a) any history of asthma or, b) onset of respiratory symptoms prior to
age 40 years.
Other protocol-defined inclusion/exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
629
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Concord
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Kogarah
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - New Lambton Heights
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Redcliffe
Query!
Recruitment hospital [5]
0
0
Novartis Investigative Site - Bedford Park
Query!
Recruitment hospital [6]
0
0
Novartis Investigative Site - Daw Park
Query!
Recruitment hospital [7]
0
0
Novartis Investigative Site - Woodville South
Query!
Recruitment hospital [8]
0
0
Novartis Investigative Site - Box Hill
Query!
Recruitment hospital [9]
0
0
Novartis Investigative Site - Fitzroy
Query!
Recruitment hospital [10]
0
0
Novartis Investigative Site - Franston
Query!
Recruitment hospital [11]
0
0
Novartis Investigative Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
2305 - New Lambton Heights
Query!
Recruitment postcode(s) [4]
0
0
4020 - Redcliffe
Query!
Recruitment postcode(s) [5]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [6]
0
0
5041 - Daw Park
Query!
Recruitment postcode(s) [7]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [8]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [9]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [10]
0
0
3199 - Franston
Query!
Recruitment postcode(s) [11]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Bruxelles
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Halen
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Liege
Query!
Country [4]
0
0
Bulgaria
Query!
State/province [4]
0
0
Pleven
Query!
Country [5]
0
0
Bulgaria
Query!
State/province [5]
0
0
Russe
Query!
Country [6]
0
0
Bulgaria
Query!
State/province [6]
0
0
Sofia
Query!
Country [7]
0
0
Bulgaria
Query!
State/province [7]
0
0
Stara Zagora
Query!
Country [8]
0
0
Bulgaria
Query!
State/province [8]
0
0
Varna
Query!
Country [9]
0
0
Bulgaria
Query!
State/province [9]
0
0
Veliko Tarnovo
Query!
Country [10]
0
0
Denmark
Query!
State/province [10]
0
0
Copenhagen NV
Query!
Country [11]
0
0
Denmark
Query!
State/province [11]
0
0
Hellerup
Query!
Country [12]
0
0
Denmark
Query!
State/province [12]
0
0
Hvidovre
Query!
Country [13]
0
0
Denmark
Query!
State/province [13]
0
0
Odense C
Query!
Country [14]
0
0
Finland
Query!
State/province [14]
0
0
Pori
Query!
Country [15]
0
0
Finland
Query!
State/province [15]
0
0
Tampere
Query!
Country [16]
0
0
Finland
Query!
State/province [16]
0
0
Turku
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Berlin
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Donaustauf
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Frankfurt
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Großhansdorf
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Hannover
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Lübeck
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Rüdersdorf
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Wiesbaden
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Witten
Query!
Country [26]
0
0
Greece
Query!
State/province [26]
0
0
Crete
Query!
Country [27]
0
0
Greece
Query!
State/province [27]
0
0
Athens - GR
Query!
Country [28]
0
0
Greece
Query!
State/province [28]
0
0
Athens
Query!
Country [29]
0
0
Greece
Query!
State/province [29]
0
0
Larissa
Query!
Country [30]
0
0
Greece
Query!
State/province [30]
0
0
Thessaloniki
Query!
Country [31]
0
0
Hong Kong
Query!
State/province [31]
0
0
Hong Kong
Query!
Country [32]
0
0
Hong Kong
Query!
State/province [32]
0
0
New Territories
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Balasagyarmat
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Budapest
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Farkasgyepu
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Kapuvár
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Nyiregyhaza
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Pécs
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Siofok
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Sopron
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Szarvas
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Veszprém
Query!
Country [43]
0
0
Israel
Query!
State/province [43]
0
0
Ashkelon
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Haifa
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Jerusalem
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Kfar-Sava
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Petach Tikva
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Rehovot
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Tel-Aviv
Query!
Country [50]
0
0
Malaysia
Query!
State/province [50]
0
0
Batu Caves
Query!
Country [51]
0
0
Malaysia
Query!
State/province [51]
0
0
Kuala Lumpur
Query!
Country [52]
0
0
Malaysia
Query!
State/province [52]
0
0
Taiping
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Bialystok
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Gdansk
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Ilawa
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Katowice
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Lodz
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Ostrow Wielkopolski
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Pila
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Poznan
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Szczecin
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Tarnow
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Wroclaw
Query!
Country [64]
0
0
Romania
Query!
State/province [64]
0
0
Jud. Constanta
Query!
Country [65]
0
0
Romania
Query!
State/province [65]
0
0
Bucharest
Query!
Country [66]
0
0
Romania
Query!
State/province [66]
0
0
Bucuresti
Query!
Country [67]
0
0
Romania
Query!
State/province [67]
0
0
Cluj Napoca
Query!
Country [68]
0
0
Romania
Query!
State/province [68]
0
0
Cluj-Napoca
Query!
Country [69]
0
0
Romania
Query!
State/province [69]
0
0
Targu Mures
Query!
Country [70]
0
0
Romania
Query!
State/province [70]
0
0
Targu-Mures
Query!
Country [71]
0
0
Singapore
Query!
State/province [71]
0
0
Singapore
Query!
Country [72]
0
0
South Africa
Query!
State/province [72]
0
0
Gauteng
Query!
Country [73]
0
0
South Africa
Query!
State/province [73]
0
0
Bloemfontein
Query!
Country [74]
0
0
South Africa
Query!
State/province [74]
0
0
Cape Town
Query!
Country [75]
0
0
South Africa
Query!
State/province [75]
0
0
Durban
Query!
Country [76]
0
0
South Africa
Query!
State/province [76]
0
0
Umkomaas
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Cataluña
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Comunidad Valenciana
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Islas Baleares
Query!
Country [80]
0
0
Sweden
Query!
State/province [80]
0
0
Göteborg
Query!
Country [81]
0
0
Sweden
Query!
State/province [81]
0
0
Lund
Query!
Country [82]
0
0
Sweden
Query!
State/province [82]
0
0
Malmö
Query!
Country [83]
0
0
Sweden
Query!
State/province [83]
0
0
Vällingby
Query!
Country [84]
0
0
Thailand
Query!
State/province [84]
0
0
Nonthaburi
Query!
Country [85]
0
0
Thailand
Query!
State/province [85]
0
0
Bangkok
Query!
Country [86]
0
0
Thailand
Query!
State/province [86]
0
0
Muang
Query!
Country [87]
0
0
Thailand
Query!
State/province [87]
0
0
Nakhon Naiyok
Query!
Country [88]
0
0
Thailand
Query!
State/province [88]
0
0
Songkla
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to
salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with
COPD
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01636076
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01636076
Download to PDF